Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma

Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.